Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of $173.61 million. The enterprise value is $184.30 million.
| Market Cap | 173.61M |
| Enterprise Value | 184.30M |
Important Dates
The last earnings date was Thursday, September 17, 2026, before market open.
| Earnings Date | Sep 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 93.83 million shares outstanding. The number of shares has increased by 10.65% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 93.83M |
| Shares Change (YoY) | +10.65% |
| Shares Change (QoQ) | +6.11% |
| Owned by Insiders (%) | 0.74% |
| Owned by Institutions (%) | 1.49% |
| Float | 70.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.49 |
| Forward PS | 15.90 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.60
| Current Ratio | 0.60 |
| Quick Ratio | 0.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -46.60% |
| Return on Invested Capital (ROIC) | -2,545.08% |
| Return on Capital Employed (ROCE) | -2,545.08% |
| Weighted Average Cost of Capital (WACC) | 8.02% |
| Revenue Per Employee | $68,325 |
| Profits Per Employee | -$330,590 |
| Employee Count | 164 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.32% in the last 52 weeks. The beta is 0.88, so Innate Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -7.32% |
| 50-Day Moving Average | 1.97 |
| 200-Day Moving Average | 1.75 |
| Relative Strength Index (RSI) | 44.00 |
| Average Volume (20 Days) | 41,999 |
Short Selling Information
The latest short interest is 81,961, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 81,961 |
| Short Previous Month | 227,041 |
| Short % of Shares Out | 0.07% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.21 |
Income Statement
In the last 12 months, Innate Pharma had revenue of $11.21 million and -$54.22 million in losses. Loss per share was -$0.58.
| Revenue | 11.21M |
| Gross Profit | -38.63M |
| Operating Income | -54.37M |
| Pretax Income | -54.22M |
| Net Income | -54.22M |
| EBITDA | -53.68M |
| EBIT | -54.37M |
| Loss Per Share | -$0.58 |
Balance Sheet
The company has $12.45 million in cash and $23.08 million in debt, with a net cash position of -$10.64 million or -$0.11 per share.
| Cash & Cash Equivalents | 12.45M |
| Total Debt | 23.08M |
| Net Cash | -10.64M |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | -46.28M |
| Book Value Per Share | -0.49 |
| Working Capital | -15.14M |
Cash Flow
In the last 12 months, operating cash flow was -$48.90 million and capital expenditures -$197,256, giving a free cash flow of -$49.09 million.
| Operating Cash Flow | -48.90M |
| Capital Expenditures | -197,256 |
| Depreciation & Amortization | 692,690 |
| Net Borrowing | -7.82M |
| Free Cash Flow | -49.09M |
| FCF Per Share | -$0.52 |
Margins
| Gross Margin | n/a |
| Operating Margin | -485.25% |
| Pretax Margin | -483.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.65% |
| Shareholder Yield | -10.65% |
| Earnings Yield | -31.23% |
| FCF Yield | -28.28% |
Analyst Forecast
The average price target for Innate Pharma is $6.67, which is 252.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.67 |
| Price Target Difference | 252.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 129.66% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |